Amyris

Amyris Stock-Based Compensation

Delisted·May 7, 2024

The Stock-Based Compensation (SBC) of Amyris (AMRSQ) as of Nov 20, 2026 is 48.71 M USD. In the previous year, Stock-Based Compensation (SBC) was 33.39 M USD — a change of 45.87% (higher).

Stock-Based Compensation

48.71 MUSD

YoY

45.87%

Last updated:

Stock-Based Compensation (SBC) of Amyris is 2022 48.71 M USD. Stock-Based Compensation (SBC) of Amyris was 2021 33.39 M USD. It decreases by 45.87% higher compared to the previous year.

The Amyris Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
12.55 M USD
Jan 1, 2020
13.74 M USD
Jan 1, 2021
33.39 M USD
Jan 1, 2022
48.71 M USD
The Amyris Stock-Based Compensation history
YEARStock-Based CompensationYoY
48.71 MUSD+45.87%
33.39 MUSD+142.99%
13.74 MUSD+9.47%
12.55 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amyris Stock analysis

What does Amyris do? Amyris Inc. is a US-based company specializing in the production of sustainable products. It was founded in 2003 and is headquartered in Emeryville, California. The company aims to promote sustainability in daily life and reduce dependence on fossil fuels. Amyris' business model is based on the discovery and development of biological microorganisms capable of converting sugars and other carbohydrates into valuable products such as fuels, chemicals, and flavors. This technology, known as synthetic biology, was first used for the production of artemisinin, which is used against malaria. Over time, Amyris has expanded its portfolio and specialized in the production of sustainable products for the cosmetics, biofuel, food, and chemical industries. Leading products include Biosolve, an environmentally friendly degreasing solution for the industry, Neossance, a plant-based moisturizer for the cosmetics industry, and Biofene, a bio-based fuel. To produce its products, the company has formed partnerships with various organizations around the world. For example, it has partnered with Total, a French oil and gas company, to establish joint ventures for the production of biofuels. Amyris has also expanded its business by developing a platform for synthetic biology that allows other industry players to develop custom organisms for production processes. This new business model has brought the company into new markets such as the medical and energy sectors. In 2020, the COVID-19 pandemic posed challenges for the company as demand for some products declined. In response, Amyris shifted its production to disinfectants to meet the increased demand for these products. Overall, Amyris has become a leading company in sustainable production and is committed to promoting innovations in synthetic biology to have a positive impact on the environment. Amyris is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amyris stock

Stock-Based Compensation (SBC) of Amyris is 48.71 M USD in 2022.

Stock-Based Compensation (SBC) of Amyris changed from 33.39 M USD to 48.71 M USD, representing a 45.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Amyris since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Amyris historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Amyris

All Key Metrics — Amyris